4:23 PM
 | 
Jun 13, 2018
 |  BC Extra  |  Company News

BridgeBio launches rare genetic disorder subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched another subsidiary this week, forming CoA Therapeutics Inc. to develop small molecules which increase coenzyme A levels to treat rare genetic disorders.

CoA CEO Shafique Virani told BioCentury that the compounds directly target pantothenate kinase 1 (PANK1) and PANK3 to up-regulate coenzyme A. The candidates were in-licensed from St....

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >